Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Melanoma exhibits significant resistance to conventional cancer therapies, including methotrexate (MTX).
• Proposed resistance mechanisms include melanosomal sequestration and cellular export of MTX, alongside general epithelial cancer resistance pathways.
• Epithelial cancer cells possess resistance mechanisms that also contribute to melanoma's resistance to MTX.

Purpose of the Study:

• To elucidate the molecular mechanisms by which melanoma achieves extreme resistance to methotrexate.
• To investigate the roles of E2F1 and checkpoint kinase 1 (Chk1) in mediating methotrexate resistance in melanoma.

Main Methods:

• Analysis of gene expression and protein activity in melanoma cells treated with methotrexate.
• Investigating the impact of dihydrofolate depletion on transcriptional activity of E2F1.
• Assessing the role of E2F1-target genes in folate metabolism and cell cycle progression.
• Evaluating the activation of Chk1 in response to DNA damage and its effect on apoptosis.

Main Results:

• Methotrexate treatment depleted dihydrofolate, stimulating E2F1 transcriptional activity.
• Elevated expression of dihydrofolate reductase and thymidylate synthase, E2F1 targets, led to dTTP accumulation.
• dTTP accumulation caused DNA single-strand breaks, activating Chk1 and inducing S-phase cell cycle arrest.
• Melanoma cells were protected from apoptosis, with excess dTTP potentially inhibiting E2F1-mediated apoptosis.

Conclusions:

• Melanoma employs a complex interplay of E2F1 and Chk1 to resist methotrexate therapy.
• Dihydrofolate depletion triggers a cascade leading to cell cycle arrest and survival, rather than apoptosis.
• Understanding these resistance mechanisms is crucial for developing more effective melanoma treatments.